Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARS Pharmaceuticals, Inc.SPRY · Entity 883 | Chief Financial Officer | January 02, 2026 | January 05, 2026 |
| Dermata Therapeutics, Inc.DRMA · Entity 8182 | Director | June 16, 2026 | June 16, 2026 |
| Histogen Inc.CNAT · Entity 112047 | Director | November 18, 2019 | November 19, 2019 |
| NKGen Biotech, Inc.NKGN · Entity 79017 | Director | December 06, 2024 | December 11, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARS Pharmaceuticals, Inc.
Report date January 02, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.49 · Expires 2036-01-01 | Direct | 240,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 240,000 · Balance 240,000 F1: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026.
Dermata Therapeutics, Inc.
Report date June 16, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Sale · Disposed 11 · Balance 0 |
| Common StockSEC Table I · non-derivative | IndirectBy Scott 2008 Trust Dated 3/28/08 | 1 |
Reported balance
Holding disclosure · report date 2026-06-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1 |
Histogen Inc.
Report date November 18, 2019 · Filed November 19, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.33 · Expires 2029-11-17 | Direct | 30,000 |
Reported balance
After 2019-11-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-11-18 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to this option become exercisable as they vest. One-third of the total number of shares subject to this option vests and becomes exercisable on each anniversary of the grant date, so that the entire number of shares subject to this option becomes fully vested and exercisable on the third anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option become exercisable as they vest. One-third of the total number of shares subject to this option vests and becomes exercisable on each anniversary of the grant date, so that the entire number of shares subject to this option becomes fully vested and exercisable on the third anniversary of the grant date.
NKGen Biotech, Inc.
Report date December 06, 2024 · Filed December 11, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.62 · Expires 2034-12-06 | Direct | 300,000 |
Reported balance
After 2024-12-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-12-06 · Grant · Acquired 300,000 · Balance 300,000 F1: On December 6, 2024, the Reporting Person was granted 300,000 options pursuant to the Company's 2023 Equity Incentive Plan, with 40% vesting immediately as of the grant date, and the remaining options vesting in 20 equal installments on the sixth day of each month, beginning January 6, 2025, and ending August 6, 2026, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.44 · Expires 2034-12-06 | Direct | 500,000 |
Reported balance
After 2024-12-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-12-06 · Grant · Acquired 500,000 · Balance 500,000 F2: On December 6, 2024, the Reporting Person was granted 500,000 options pursuant to the Company's 2023 Equity Incentive Plan, vesting in 36 equal installments on the sixth of each month, beginning January 6, 2025, and ending December 6, 2027, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 6, 2024, the Reporting Person was granted 300,000 options pursuant to the Company's 2023 Equity Incentive Plan, with 40% vesting immediately as of the grant date, and the remaining options vesting in 20 equal installments on the sixth day of each month, beginning January 6, 2025, and ending August 6, 2026, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.
F2: On December 6, 2024, the Reporting Person was granted 500,000 options pursuant to the Company's 2023 Equity Incentive Plan, vesting in 36 equal installments on the sixth of each month, beginning January 6, 2025, and ending December 6, 2027, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 16, 2026 20:15 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | SaleCommon Stock | 11 | $1.19 | $13.09 |
DisclosureSEC source: 0001493152-26-028884 · ownership.xml · nonDerivative · entry 1 Scott Kathleen D. · CIK 0001794284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:27 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 240,000 | $0.00 Strike: $11.49 | $0.00 |
DisclosureSEC source: 0001794284-26-000002 · form4-01052026_090134.xml · derivative · entry 1 Scott Kathleen D. · CIK 0001794284 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 01:00 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001493152-26-000697 · ownership.xml · derivative · entry 1 Scott Kathleen D. · CIK 0001794284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2036-01-01 F1 · derivative.exercise_date: The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| August 21, 2025 Filed Aug 22, 2025 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-25-022760 · form4-08222025_040801.xml · derivative · entry 4 Scott Kathleen D. · CIK 0001794284 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 739,830 Underlying: Common Stock · 12,500 shares Expires 2032-02-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| August 21, 2025 Filed Aug 22, 2025 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 12,500 | $15.00 | $187,500.00 |
DisclosureSEC source: 0001415889-25-022760 · form4-08222025_040801.xml · nonDerivative · entry 2 Scott Kathleen D. · CIK 0001794284 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,042 F2 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on May 22, 2025. Read SEC document |
| August 21, 2025 Filed Aug 22, 2025 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 12,500 | $1.50 | $18,750.00 |
DisclosureSEC source: 0001415889-25-022760 · form4-08222025_040801.xml · nonDerivative · entry 1 Scott Kathleen D. · CIK 0001794284 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,618 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2025. Read SEC document |
| May 20, 2025 Filed May 22, 2025 21:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-25-014184 · form4-05222025_050501.xml · derivative · entry 4 Scott Kathleen D. · CIK 0001794284 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 752,330 Underlying: Common Stock · 50,000 shares Expires 2032-02-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| May 20, 2025 Filed May 22, 2025 21:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $14.10 | $705,165.00 |
DisclosureSEC source: 0001415889-25-014184 · form4-05222025_050501.xml · nonDerivative · entry 2 Scott Kathleen D. · CIK 0001794284 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,424 F2 · price: The weighted average sale price for the transaction reported was $14.1033 and the range of prices were between $14.10 and $14.115. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 20, 2025 Filed May 22, 2025 21:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 50,000 | $1.50 | $75,000.00 |
DisclosureSEC source: 0001415889-25-014184 · form4-05222025_050501.xml · nonDerivative · entry 1 Scott Kathleen D. · CIK 0001794284 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,475 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2024. Read SEC document |
| January 13, 2025 Filed Jan 14, 2025 23:49 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001654954-25-000396 · section16.xml · derivative · entry 1 Scott Kathleen D. · CIK 0001794284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2035-01-12 F1 · derivative.exercise_date: The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 176,700 | $0.00 Strike: $10.71 | $0.00 |
DisclosureSEC source: 0001415889-25-000460 · form4-01032025_040124.xml · derivative · entry 1 Scott Kathleen D. · CIK 0001794284 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,700 Underlying: Common Stock · 176,700 shares Expires 2035-01-01 F1 · derivative.exercise_date: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2025. Read SEC document |
| December 06, 2024 Filed Dec 11, 2024 02:56 UTC | NKGen Biotech, Inc. NKGN · Entity 79017 | GrantStock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0001213900-24-107608 · ownership.xml · derivative · entry 2 Scott Kathleen D. · CIK 0001794284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2034-12-06 F2 · derivative.exercise_date: On December 6, 2024, the Reporting Person was granted 500,000 options pursuant to the Company's 2023 Equity Incentive Plan, vesting in 36 equal installments on the sixth of each month, beginning January 6, 2025, and ending December 6, 2027, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. Read SEC document |
| December 06, 2024 Filed Dec 11, 2024 02:56 UTC | NKGen Biotech, Inc. NKGN · Entity 79017 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001213900-24-107608 · ownership.xml · derivative · entry 1 Scott Kathleen D. · CIK 0001794284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2034-12-06 F1 · derivative.exercise_date: On December 6, 2024, the Reporting Person was granted 300,000 options pursuant to the Company's 2023 Equity Incentive Plan, with 40% vesting immediately as of the grant date, and the remaining options vesting in 20 equal installments on the sixth day of each month, beginning January 6, 2025, and ending August 6, 2026, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. Read SEC document |
| October 16, 2024 Filed Oct 17, 2024 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-24-025370 · form4-10172024_041028.xml · derivative · entry 4 Scott Kathleen D. · CIK 0001794284 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 802,330 Underlying: Common Stock · 12,500 shares Expires 2032-02-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| October 16, 2024 Filed Oct 17, 2024 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 12,500 | $16.00 | $200,000.00 |
DisclosureSEC source: 0001415889-24-025370 · form4-10172024_041028.xml · nonDerivative · entry 2 Scott Kathleen D. · CIK 0001794284 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,949 F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2024. Read SEC document |
| October 16, 2024 Filed Oct 17, 2024 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 12,500 | $1.50 | $18,750.00 |
DisclosureSEC source: 0001415889-24-025370 · form4-10172024_041028.xml · nonDerivative · entry 1 Scott Kathleen D. · CIK 0001794284 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,449 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The Reporting Person inadvertently added the holdings of Scott 2008 Trust Dated 3/28/08 (the "Trust") as directly held on her Form 4 filed on August 20, 2024. As of the date of that Form 4, the Reporting Person owned 8,250 shares indirectly through the Trust. Read SEC document |
| August 20, 2024 Filed Aug 21, 2024 22:49 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-24-021882 · form4-08212024_100844.xml · derivative · entry 3 Scott Kathleen D. · CIK 0001794284 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 814,830 Underlying: Common Stock · 12,500 shares Expires 2032-02-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| August 20, 2024 Filed Aug 21, 2024 22:49 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 12,500 | $16.00 | $200,000.00 |
DisclosureSEC source: 0001415889-24-021882 · form4-08212024_100844.xml · nonDerivative · entry 2 Scott Kathleen D. · CIK 0001794284 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,199 F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2024. Read SEC document |
| August 20, 2024 Filed Aug 21, 2024 22:49 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 12,500 | $1.50 | $18,750.00 |
DisclosureSEC source: 0001415889-24-021882 · form4-08212024_100844.xml · nonDerivative · entry 1 Scott Kathleen D. · CIK 0001794284 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,699 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,969 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") on June 30, 2023 and 1,980 shares acquired under the ESPP on June 28, 2024. Read SEC document |
| February 12, 2024 Filed Feb 15, 2024 01:20 UTC | NKGen Biotech, Inc. NKGN · Entity 79017 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001104659-24-024197 · tm246293-5_4seq1.xml · derivative · entry 1 Scott Kathleen D. · CIK 0001794284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires not disclosed F1 · derivative.exercise_date: On February 12, 2024, the reporting person was granted 300,000 options pursuant to the Company's 2023 Equity Incentive Plan, vesting in equal installments on the first of each month, beginning October 1, 2023, and ending October 1, 2026, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. F1 · derivative.expiration_date: On February 12, 2024, the reporting person was granted 300,000 options pursuant to the Company's 2023 Equity Incentive Plan, vesting in equal installments on the first of each month, beginning October 1, 2023, and ending October 1, 2026, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. Read SEC document |
| January 04, 2024 Filed Jan 6, 2024 02:01 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001654954-24-000297 · section16.xml · derivative · entry 1 Scott Kathleen D. · CIK 0001794284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-01-03 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing January 4, 2024. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:39 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 200,000 | $0.00 Strike: $5.58 | $0.00 |
DisclosureSEC source: 0001209191-24-000805 · doc4.xml · derivative · entry 1 Scott Kathleen D. · CIK 0001794284 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 1, 2025, and the remaining shares will vest monthly thereafter over three years. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 22:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $8.42 | $0.00 |
DisclosureSEC source: 0001209191-23-001933 · doc4.xml · derivative · entry 1 Scott Kathleen D. · CIK 0001794284 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-01-02 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2024, and the remaining shares will vest monthly thereafter over three years. Read SEC document |
| November 29, 2022 Filed Dec 1, 2022 21:31 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | PurchaseCommon Stock | 8,250 | $6.24 | $51,506.40 |
DisclosureSEC source: 0001209191-22-059187 · doc4.xml · nonDerivative · entry 1 Scott Kathleen D. · CIK 0001794284 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 8,250 F1 · price: The price reported in Column 4 is the weighted average price. The shares were sold in multiple transactions at prices ranging from $6.16 to $6.26, inclusive. Upon request by the Securities and Exchange Commission staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. F2 · ownership.nature: By Scott 2008 Trust Dated 3/28/08. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 23:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantEmployee Stock Option (right to buy) · Derivative | 827,330 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001209191-22-056438 · doc4.xml · derivative · entry 1 Scott Kathleen D. · CIK 0001794284 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 827,330 Underlying: Common Stock · 827,330 shares Expires 2032-03-01 F2 · price: Received in exchange for a stock option to acquire 700,000 shares of common stock of ARS Pharmaceuticals, Inc. ("ARS") with the exercise price of $1.77 per share pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), as amended (the "Merger Agreement"). Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc. F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date. Read SEC document |
| October 06, 2022 Filed Oct 7, 2022 21:05 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantCommon Stock | 11,359 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-013526 · section16.xml · nonDerivative · entry 1 Scott Kathleen D. · CIK 0001794284 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,145 F1 · date: On October 6, 2022, the Reporting Person was granted 11,359 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 20:10 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantCommon Stock | 9,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-009454 · section16.xml · nonDerivative · entry 1 Scott Kathleen D. · CIK 0001794284 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,786 F1 · shares: On July 7, 2022, the Reporting Person was granted 9,960 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan. Read SEC document |
| April 07, 2022 Filed Apr 8, 2022 23:17 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantCommon Stock | 5,826 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-22-000568 · dermata_fm4apr72022.xml · nonDerivative · entry 1 Scott Kathleen D. · CIK 0001794284 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,826 F1 · shares: On April 7, 2022, the Reporting Person was granted 5,826 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:05 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0000905718-22-000044 · dermata_fm4jan32022.xml · derivative · entry 1 Scott Kathleen D. · CIK 0001794284 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2032-01-02 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing January 3, 2022. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 16:47 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0000905718-21-001106 · dermata_fm4aug172021.xml · derivative · entry 1 Scott Kathleen D. · CIK 0001794284 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-08-17 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing September 17, 2021. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 16:10 UTC | Histogen Inc. CNAT · Entity 112047 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001209191-19-057129 · doc4.xml · derivative · entry 1 Scott Kathleen D. · CIK 0001794284 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-11-17 F1 · derivative.exercise_date: The shares subject to this option become exercisable as they vest. One-third of the total number of shares subject to this option vests and becomes exercisable on each anniversary of the grant date, so that the entire number of shares subject to this option becomes fully vested and exercisable on the third anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.